MOTS-C

MOTS-c — The Exercise Mimetic & Longevity Peptide

MOTS-c is a 16-amino acid mitochondrial-encoded peptide translated from an open reading frame within the mitochondrial 12S rRNA gene. It is studied as an exercise-responsive metabolic signal, with some studies reporting increases in endogenous MOTS-c levels during physical activity and associations with skeletal muscle adaptation, insulin sensitivity, and age-related physical performance. Its primary use case is investigational research into metabolic aging, muscle metabolism, and mitochondrial stress adaptation.

MOTS-c is often described as having exercise-like metabolic signaling properties because its endogenous expression has increased in response to physical activity in some studies, though this effect is not uniformly observed across all populations. Researchers associated exercise with increased MOTS-c levels in human skeletal muscle and circulation, while MOTS-c administration improved physical performance and healthspan-related measures in mouse models.

These findings inform ongoing research into MOTS-c and physical performance. However, performance-related effects are supported primarily by preclinical data, with human evidence currently limited to biomarker observations rather than validated clinical outcomes.

Interest in longevity and metabolic health stems from MOTS-c’s role in metabolic stress responses. Research suggests that endogenous levels may vary in association with:

• Age
• Obesity
• Insulin resistance

Review literature also describes MOTS-c as a mitochondrial-derived peptide under investigation for potential relevance in:

• Aging biology
• Metabolic disorders
• Cardiovascular research
• Insulin resistance

MOTS-c remains an investigational research compound and is not approved by the U.S. Food and Drug Administration for therapeutic use.

What is MOTS-c? Mitochondrial-derived Peptide Explained

Understanding what MOTS-c is matters because it has helped broaden researchers’ view of mitochondria—not only as energy-producing organelles but also as sources of bioactive peptides that can act as systemic metabolic signals.

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a mitochondrial-encoded peptide, meaning its sequence originates from mitochondrial DNA rather than nuclear DNA. The original 2015 Cell Metabolism study by Lee et al. reported that MOTS-c influences metabolic regulation through the folate–purine–AMPK pathway and was associated with reduced weight gain and improved insulin sensitivity in mouse models.

This mitochondrial origin is relevant to ongoing research into cellular stress responses and aging. MOTS-c has been shown in preclinical studies to translocate to the nucleus under metabolic stress and modulate nuclear gene expression, supporting its proposed role as a mitochondria-to-nucleus signaling molecule.

In current professional discussions, MOTS-c is primarily studied for its potential relevance to:

• Metabolic health and insulin sensitivity
• Skeletal muscle metabolism and physical performance
• Aging and longevity-related pathways

Human evidence remains limited, with the strongest functional data derived from animal and cell models. Those looking to buy MOTS-c for longevity or metabolic performance research can contact Medica Depot’s support representatives for sourcing guidance.

MOTS-c Mechanism and Metabolic Benefits

MOTS-c primarily acts through AMP-activated protein kinase (AMPK), a key regulator of cellular energy balance. Through AMPK-linked pathways, MOTS-c has been studied for its role in glucose uptake, fatty acid oxidation, skeletal muscle metabolism, and metabolic flexibility.

In preclinical models, Lee et al. reported that MOTS-c helped reduce obesity and insulin resistance in mice, with skeletal muscle identified as an important target tissue. MOTS-c may also function as a mitochondria-to-nucleus signal, helping regulate nuclear gene expression during metabolic stress.

The main MOTS-c benefits discussed in research include improved physical performance, insulin sensitivity, metabolic flexibility, and longevity-related markers. Reynolds et al. found that MOTS-c improved physical performance in mice across age groups, while early human data indicate that exercise can increase circulating MOTS-c levels. These findings should be framed carefully: current evidence supports biomarker relevance and preclinical performance effects, not validated human performance enhancement.

MOTS-c Dosage, When to Take, and WADA Status

MOTS-c dosage references should be framed as practitioner-reported or research-extrapolated. No validated human dosing protocol exists, and MOTS-c is not approved as a prescription medicine.

Common points discussed in practitioner settings include:

• Dose range: MOTS-c is commonly referenced at around 5 to 10 mg per week by subcutaneous injection. This should be presented as a research-use reference only, not as clinical guidance.
• Timing: When to take the MOTS-c peptide is usually discussed in relation to metabolic timing. Morning dosing is often referenced for circadian alignment, while pre-exercise timing is sometimes discussed because endogenous MOTS-c levels increase during physical activity.
• Cycle structure: Some practitioner-reported frameworks describe continuous weekly use, while others use cycling protocols with breaks to assess response. No long-term human protocol has been validated.
• Reconstitution and storage: Lyophilized MOTS-c is commonly reconstituted with bacteriostatic water. After reconstitution, it is typically stored at 2 to 8°C, protected from light, and handled in accordance with product-specific documentation.
• WADA status: MOTS-c is not explicitly named on recent WADA Prohibited Lists. However, the WADA Prohibited List is updated annually, and WADA category language can capture related substance classes. Athletes should verify the most up-to-date list and consult anti-doping professionals before any discussion of protocols.

MOTS-c Side Effects

MOTS-c side effects remain incompletely characterized in humans. Available preclinical and limited human biomarker data do not establish a comprehensive therapeutic safety profile. Regulatory agencies, including the U.S. Food and Drug Administration, have noted limited publicly available human safety data and have raised concerns regarding compounded MOTS-c products.

In practitioner-reported injectable contexts, some individuals have described mild, non-specific reactions consistent with subcutaneous administration. These may include:

• Redness at the injection site
• Swelling or localized inflammation
• Tenderness or temporary discomfort

These reactions are not unique to MOTS-c and are commonly reported with other injectable peptides.

No serious adverse events are well established in controlled human therapeutic studies, largely because such studies remain limited or absent. Key safety considerations that have not been adequately defined include:

• Long-term safety
• Immunogenicity
• Dose-response relationships
• Route-specific risks across different administration methods

Legal Status of MOTS-c

Regulatory information below is current as of May 2026 and is subject to change. Practitioners should verify jurisdiction-specific regulations before evaluation or procurement.

• United States: MOTS-c is not FDA-approved for human therapeutic use. FDA materials identify compounded drugs containing MOTS-c as presenting potential risk concerns, including immunogenicity and peptide impurity or API characterization issues. There is limited publicly available human safety data for MOTS-c administered by any route. Practitioners should verify the current FDA status and compounding restrictions before making any protocol or procurement decisions.
• Australia: MOTS-c is not TGA-approved for therapeutic use. Practitioners should verify current local compounding and importation requirements before any patient-facing or protocol-related discussion.
• WADA: MOTS-c is not currently listed on the WADA Prohibited List. Practitioners working with competitive athletes should advise them to independently confirm their current WADA status, as the Prohibited List is updated annually.

Those considering buying MOTS-c wholesale for institutional research can contact Medica Depot’s support representatives for documentation and guidance. Practitioners evaluating research compounds when buying online should consider legal status, product characterization, certificate of analysis documentation, sterility controls, and cold-chain handling before engaging with any supplier.

MOTS-c vs SS-31, NAD, and AOD

MOTS-c falls within a broader category of mitochondrial and metabolic longevity peptides, but it has a distinct mechanism and tissue focus. Comparing it with SS-31, NAD, and AOD helps clarify how these compounds influence mitochondrial health, aging, and metabolic function via distinct pathways.

MOTS-c is distinct from SS-31 because it is positioned as an exercise-responsive metabolic signal rather than a mitochondrial membrane stabilizer. SS-31 research focuses more directly on cardiolipin, electron transport chain function, and oxidative stress protection.

Compared with NAD, MOTS-c is narrower but more mechanistically specific. NAD strategies focus on cellular energy pools, sirtuin biology, and DNA repair support, whereas MOTS-c is tightly coupled to AMPK, skeletal muscle metabolism, and exercise-like signaling.

Compared with AOD, MOTS-c is less focused on direct fat oxidation and more focused on metabolic flexibility and insulin sensitivity. AOD is discussed primarily as an hGH-fragment-derived fat metabolism peptide, while MOTS-c is framed as a mitochondrial-derived exercise mimetic.

Where Can Practitioners Buy MOTS-c Online?

Access to MOTS-c is limited to qualified professionals conducting investigational research in metabolic aging, exercise physiology, or longevity medicine. Suppliers should be able to provide a complete analytical package: certificate of analysis, lot-specific purity data, API characterization documentation, and evidence of appropriate cold-chain handling. Medica Depot can connect qualified researchers with sourcing guidance and relevant documentation. The product is also available for wholesale purchase, interested practitioners can reach out to Medica Depot’s support team to discuss your procurement needs and directions for sourcing.

FAQs

1. What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-encoded peptide translated from the 12S rRNA region of mitochondrial DNA. It is studied as an exercise mimetic and longevity peptide because it influences metabolic stress signaling, muscle metabolism, and insulin sensitivity in preclinical models. It remains a research compound and is not FDA-approved for therapeutic use.

2. What is the MOTS-c peptide used for?

MOTS-c is studied for its effects on longevity, metabolic health, insulin resistance, physical performance, and anti-aging. The strongest functional evidence comes from animal models, while human data mainly involve endogenous MOTS-c levels and exercise-associated biomarker changes. It should not be presented as a clinically validated therapy.

3. What are MOTS-c benefits?

Research on MOTS-c benefits includes improvements in physical performance, metabolic flexibility, insulin sensitivity, and longevity-related markers. Reynolds et al. reported physical performance benefits in mice, while human data show exercise-related changes in MOTS-c levels. These findings are promising but remain evidence-tiered and are not equivalent to approved clinical outcomes.

4. What is the MOTS-c dosage?

Practitioner-reported MOTS-c dosage commonly ranges from 5 to 10 mg weekly by subcutaneous injection. This is not a validated human dosing protocol and should be described only as a research-use reference. Individual assessment and regulatory review are required before any protocol decision.

5. When to take MOTS-c peptide?

Morning dosing is often discussed to align with circadian rhythms and metabolic activity. Pre-exercise timing is sometimes referenced because endogenous MOTS-c levels increase during physical activity, though this has not been validated through controlled human dosing trials. These timing approaches are extrapolated from preclinical and observational data.

6. What are the MOTS-c side effects?

MOTS-c side effects are not fully characterized in humans. Practitioner-reported concerns include mild injection-site reactions, while FDA materials note gaps in human exposure, immunogenicity, and product characterization. Long-term safety data are absent, and athletes should verify their current World Anti-Doping Agency status before any consideration.

Citations

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. Published 2021 Jan 20. doi:10.1038/s41467-020-20790-0

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.